Ovid Therapeutics Expands Scientific Advisory Board to Enhance Neurology Research

Ovid Therapeutics Inc. has expanded its Scientific Advisory Board with leading neurologists and neuroscientists to enhance its innovative pipeline for treating rare epilepsies and brain disorders. The board, chaired by Professor Robert Langer, aims to advance research on compounds targeting ROCK2 inhibition and KCC2 activation, potentially transforming treatment for complex neurological conditions.